Liver cirrhosis
- PMID: 34543610
- DOI: 10.1016/S0140-6736(21)01374-X
Liver cirrhosis
Abstract
Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C infection, autoimmune diseases, cholestatic diseases, and iron or copper overload. Cirrhosis develops after a long period of inflammation that results in replacement of the healthy liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension. The disease evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which often result in hospitalisation, impaired quality of life, and high mortality. Progressive portal hypertension, systemic inflammation, and liver failure drive disease outcomes. The management of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation can be required in some cases. In this Seminar, we discuss the disease burden, pathophysiology, and recommendations for the diagnosis and management of cirrhosis and its complications. Future challenges include better screening for early fibrosis or cirrhosis, early identification and reversal of causative factors, and prevention of complications.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests PG reports research funding from Gilead Sciences, Mallinckrodt Pharmaceuticals, and Grifols; and participation in advisory boards for Gilead Sciences, Grifols, Mallinckrodt, Novartis, Martin Pharmaceuticals, and Ferring. AK is a speaker and advisory board member for Norgine and Siemens. JGA is a consultant for Gilead Sciences, Intercept, Genfit, Lupin, Inventiva, and Boehringer Ingelheim; and reports grant support from Gilead Sciences and speaker fees from Lupin. NF participated in advisory boards for Intercept. PSK is an advisory board member of Sequana. ES declares no competing interests.
Similar articles
-
Presentation and complications associated with cirrhosis of the liver.Curr Med Res Opin. 2015 May;31(5):925-37. doi: 10.1185/03007995.2015.1021905. Curr Med Res Opin. 2015. PMID: 25697811 Review.
-
Impact of physical and psychological factors on health-related quality of life in adult patients with liver cirrhosis: a systematic review protocol.JBI Database System Rev Implement Rep. 2015 Jan;13(1):39-51. doi: 10.11124/jbisrir-2015-1987. JBI Database System Rev Implement Rep. 2015. PMID: 26447006
-
The emergency medicine evaluation and management of the patient with cirrhosis.Am J Emerg Med. 2018 Apr;36(4):689-698. doi: 10.1016/j.ajem.2017.12.047. Epub 2017 Dec 23. Am J Emerg Med. 2018. PMID: 29290508 Review.
-
Liver cirrhosis.Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):281-90. doi: 10.1016/j.bpg.2011.02.009. Best Pract Res Clin Gastroenterol. 2011. PMID: 21497745 Review.
-
[Clinical symptoms of patients with liver cirrhosis].Nihon Rinsho. 1994 Jan;52(1):40-4. Nihon Rinsho. 1994. PMID: 8114308 Japanese.
Cited by
-
Refractory massive chylothorax following robot-assisted laparoscopic splenectomy with pericardial devascularization treated with trans-jugular intrahepatic portosystemic shunt: a case report.Front Med (Lausanne). 2024 Sep 4;11:1420157. doi: 10.3389/fmed.2024.1420157. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39296890 Free PMC article.
-
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.Int J Mol Sci. 2023 Nov 19;24(22):16502. doi: 10.3390/ijms242216502. Int J Mol Sci. 2023. PMID: 38003692 Free PMC article. Review.
-
Fractional order differential equations for chronic liver cirrhosis with frequent hospitalization.BMC Res Notes. 2022 Oct 22;15(1):332. doi: 10.1186/s13104-022-06223-9. BMC Res Notes. 2022. PMID: 36273195 Free PMC article.
-
18beta-glycyrrhetinic acid induces ROS-mediated apoptosis to ameliorate hepatic fibrosis by targeting PRDX1/2 in activated HSCs.J Pharm Anal. 2022 Aug;12(4):570-582. doi: 10.1016/j.jpha.2022.06.001. Epub 2022 Jun 8. J Pharm Anal. 2022. PMID: 36105163 Free PMC article.
-
The role of hepatic microenvironment in hepatic fibrosis development.Ann Med. 2022 Dec;54(1):2830-2844. doi: 10.1080/07853890.2022.2132418. Ann Med. 2022. PMID: 36399108 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical